Neumora Therapeutics Statistics
Total Valuation
NMRA has a market cap or net worth of $1.76 billion. The enterprise value is $1.51 billion.
Important Dates
The next confirmed earnings date is Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NMRA has 160.03 million shares outstanding. The number of shares has increased by 348.64% in one year.
| Current Share Class | 160.03M |
| Shares Outstanding | 160.03M |
| Shares Change (YoY) | +348.64% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 5.84% |
| Owned by Institutions (%) | 45.23% |
| Float | 83.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.91 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.22, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.22 |
| Quick Ratio | 16.14 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -77.08% and return on invested capital (ROIC) is -39.98%.
| Return on Equity (ROE) | -77.08% |
| Return on Assets (ROA) | -37.75% |
| Return on Capital (ROIC) | -39.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.21M |
| Employee Count | 124 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NMRA has paid $393,000 in taxes.
| Income Tax | 393,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.84% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -6.84% |
| 50-Day Moving Average | 12.91 |
| 200-Day Moving Average | 12.65 |
| Relative Strength Index (RSI) | 35.12 |
| Average Volume (20 Days) | 1,336,794 |
Short Selling Information
The latest short interest is 9.01 million, so 5.63% of the outstanding shares have been sold short.
| Short Interest | 9.01M |
| Short Previous Month | 9.68M |
| Short % of Shares Out | 5.63% |
| Short % of Float | 10.80% |
| Short Ratio (days to cover) | 7.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -230.86M |
| Pretax Income | -273.79M |
| Net Income | -274.18M |
| EBITDA | -230.20M |
| EBIT | -230.86M |
| Earnings Per Share (EPS) | -$2.12 |
Full Income StatementBalance Sheet
The company has $371.64 million in cash and $3.61 million in debt, giving a net cash position of $368.03 million or $2.30 per share.
| Cash & Cash Equivalents | 371.64M |
| Total Debt | 3.61M |
| Net Cash | 368.03M |
| Net Cash Per Share | $2.30 |
| Equity (Book Value) | 381.26M |
| Book Value Per Share | 2.38 |
| Working Capital | 375.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$198.33 million and capital expenditures -$856,000, giving a free cash flow of -$199.18 million.
| Operating Cash Flow | -198.33M |
| Capital Expenditures | -856,000 |
| Free Cash Flow | -199.18M |
| FCF Per Share | -$1.24 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |